MD4300B1 - Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel - Google Patents

Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel

Info

Publication number
MD4300B1
MD4300B1 MDA20120128A MD20120128A MD4300B1 MD 4300 B1 MD4300 B1 MD 4300B1 MD A20120128 A MDA20120128 A MD A20120128A MD 20120128 A MD20120128 A MD 20120128A MD 4300 B1 MD4300 B1 MD 4300B1
Authority
MD
Moldova
Prior art keywords
liver cancer
cell proliferation
inhibitor
hepg2 cell
thiosemicarbazono
Prior art date
Application number
MDA20120128A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD4300C1 (en
Inventor
Aurelian Gulea
Angela Jalbă
Victor Ţapcov
Sergiu Şova
Donald Poirier
Aliona Cotovaia
Original Assignee
Universitatea De Stat Din Moldova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitatea De Stat Din Moldova filed Critical Universitatea De Stat Din Moldova
Priority to MDA20120128A priority Critical patent/MD4300C1/en
Publication of MD4300B1 publication Critical patent/MD4300B1/en
Publication of MD4300C1 publication Critical patent/MD4300C1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to chemistry, namely to the synthesis of coordinative compounds from the class of thiosemicarbazonates of transition metals and can be used in medicine as cytostatic agent in the prophylaxis and treatment of liver cancer.Summary of the invention consists in the fact that as inhibitor of HepG2 cell proliferation in liver cancer is proposed the use of a new compound, chloro-¢2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel of formula:The claimed compound exhibits itself as an effective inhibitor of HepG2 cell proliferation in liver cancer at concentrations of 10-5 - 10-6 mol/L.
MDA20120128A 2012-12-28 2012-12-28 Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel MD4300C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20120128A MD4300C1 (en) 2012-12-28 2012-12-28 Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20120128A MD4300C1 (en) 2012-12-28 2012-12-28 Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel

Publications (2)

Publication Number Publication Date
MD4300B1 true MD4300B1 (en) 2014-08-31
MD4300C1 MD4300C1 (en) 2015-03-31

Family

ID=51485231

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20120128A MD4300C1 (en) 2012-12-28 2012-12-28 Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel

Country Status (1)

Country Link
MD (1) MD4300C1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4407C1 (en) * 2015-04-29 2016-10-31 Государственный Университет Молд0 Inhibitor of human myeloid leukemia HL-60 cells based on bis[N-(prop-2-en-1-yl)-2-(pyridine-2-ylmethylidene)hydrazinecarbothioamide]nickel(II) chloride hydrate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD890G2 (en) * 1996-06-24 1998-07-31 Николае ЕРЕМИЯ Method for animals immunologic system potetiation
CN102038934B (en) * 2005-11-03 2012-08-29 福建医科大学 Application of cucurmosin in preparation of drug for treating breast cancer
CA2649324A1 (en) * 2006-04-12 2007-10-25 Jean-Damien Charrier Tetrahydropteridines useful as inhibitors of protein kinases
CN101204401B (en) * 2007-12-14 2010-05-19 中国科学院南海海洋研究所 Sea hedgehog extractive, preparation method and anticancer application thereof
CN100569781C (en) * 2007-12-14 2009-12-16 中国科学院南海海洋研究所 A kind of dimeric flavones compound and preparation method thereof and the application in the preparation cancer therapy drug
CN101333236A (en) * 2008-08-05 2008-12-31 浙江大学 Method for preparing clitocine and applications in antineoplastic medicaments
CN102219822B (en) * 2011-03-24 2013-01-09 上海交通大学 Ganoderic acid T amide derivative TLTO-A and synthetic method and application thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4407C1 (en) * 2015-04-29 2016-10-31 Государственный Университет Молд0 Inhibitor of human myeloid leukemia HL-60 cells based on bis[N-(prop-2-en-1-yl)-2-(pyridine-2-ylmethylidene)hydrazinecarbothioamide]nickel(II) chloride hydrate

Also Published As

Publication number Publication date
MD4300C1 (en) 2015-03-31

Similar Documents

Publication Publication Date Title
PH12016501375A1 (en) Pyridin-2-amides useful as cb2 agonists
PH12016500225A1 (en) Novel quinoline-substituted compound
NZ705705A (en) Ret inhibitor
EA201390794A1 (en) BICYCLIC COMPOUND
NZ715747A (en) Syk inhibitors
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
EA201290800A1 (en) Heterocyclic Compound
EA201200102A1 (en) COMPOUNDS APPLICABLE AS A MEDICINE
EA201591624A1 (en) NEW PIRAZOL DERIVATIVES
MY182328A (en) Pyridine-2-amides useful as cb2 agonists
MX2020005533A (en) Novel process for making compounds for use in the treatment of cancer.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX2014002988A (en) Process and composition for inhibiting the polymerization of cyclopentadiene compounds.
MX2016008259A (en) Process methods for phosphatidylinositol 3-kinase inhibitors.
MX338885B (en) Compounds useful in the synthesis of benzamide compounds.
EA201591498A1 (en) AZETIDINYLOXYPHENYLPYRROLIDINE COMPOUNDS
GB201107985D0 (en) Process
MX2015016766A (en) Novel tetrazolone derivatives.
EA201401277A1 (en) METHANTION COMPOUNDS WITH ANTI-VIRUS ACTIVITY
MD4300B1 (en) Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel
MX2015014728A (en) Synthesis of bace inhibitors.
MD4258C1 (en) The use of biologically active coordinative compounds of copper(II) with 4-(methoxyphenyl)thiosemicarbazones of 2-benzoylpyridine as inhibitors of Candida albicans
UY33803A (en) MODIFIED RELEASE DOSING FORMS NOVEDOSAS XANTINA OXIDORREDUCTASA INHIBITORS OR XANTINA OXIDASA INHIBITORS
MX2016007130A (en) Novel method for the synthesis of 7-methoxy-naphthalene-1-carbald ehyde and use thereof in the synthesis of agomelatine.
TH163132B (en) A benzylamine derivative that is a plasma calicrene inhibitor.

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees